#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Superficial vein thrombosis Diabetes insipidus Medullary thyroid cancer Acute leukaemia Cystic fibrosis lung Eosinophilic oesophagitis Angiosarcoma metastatic Epstein-Barr virus infection Non-small cell lung cancer metastatic Intracranial calcification Homocystinuria Necrotising enterocolitis neonatal Encephalopathy neonatal Cutaneous lupus erythematosus Waldenstrom's macroglobulinaemia refractory More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis II – Treatment Haemophagocytic lymphohistiocytosis – Basic Information Hairy cell leukaemia – Trials in Disease Alexander disease – Trials in Disease Mast cell activation syndrome Primary hyperoxaluria – Trials in Disease Idiopathic inflammatory myopathy – Basic Information Lymphatic malformation Splenic marginal zone lymphoma – Basic Information Lymphangiosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Setmelanotide Telisotuzumab Vedotin TEV-53408 Lymecycline Pemetrexed Ag-946 HYDROXYCHLOROQUINE Mcla-129 Topotecan Hydrochloride Aflibercept Blu-451 Metreleptin Polatuzumab Vedotin ALFENTANIL HYDROCHLORIDE Nifedipine Sunvozertinib Escitalopram Fostemsavir Human Coagulation Factor Ii Ads-010 More therapies…

    Learn about Your Condition

    Cardiac amyloidosis Prodromal Alzheimer's disease Depression B-cell lymphoma recurrent Proteinuria Dermatomyositis Intracranial aneurysm Neuroblastoma Ewing's sarcoma recurrent Haemorrhage prophylaxis Sleep disorder Still's disease Agitation Pseudomyxoma peritonei Anxiety disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. General University Hospital Of Larissa

General University Hospital Of Larissa

P. O. Box 1425, Larissa, 411 10, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

    Not recruiting

    3 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Ibrutinib
    Austria Belgium Czechia France Greece Hungary +5

  • Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Gastric cancer
    Investigated Drugs:
    • Bemarituzumab
    • Fluorouracil
    • Folinic Acid
    Belgium Bulgaria Czechia Denmark Estonia France +12

  • Study on the Effects of Bexotegrast for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    4 1
    Investigated Diseases:
    • Idiopathic pulmonary fibrosis
    Investigated Drugs:
    • Bexotegrast
    Belgium Czechia Denmark France Germany Greece +5

  • Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Atezolizumab
    • Trastuzumab
    • Trastuzumab Emtansine
    Austria Belgium Bulgaria Czechia Denmark France +8

  • Study on the Effectiveness and Safety of Fluticasone Propionate and Salbutamol Sulfate for Patients with Asthma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Asthma
    Investigated Drugs:
    • Salbutamol Sulfate
    • Fluticasone Propionate
    Bulgaria Czechia Denmark Germany Greece Hungary +6

  • Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Evolocumab
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Tucatinib
    • Pertuzumab
    • Trastuzumab
    Austria Belgium Czechia Finland France Germany +6

  • Study Comparing Brinzolamide and Timolol Eye Drops for Patients with Glaucoma or Ocular Hypertension

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Brinzolamide
    • Timolol
    Greece

  • Study to Compare Fianlimab and Cemiplimab Combination with Cemiplimab Alone for Adults with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    France Greece Romania Spain

  • Study on Fipaxalparant for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    2 1
    Investigated Diseases:
    • Idiopathic pulmonary fibrosis
    Investigated Drugs:
    • Fipaxalparant
    France Greece Italy The Netherlands Poland Spain
Previous Page
1 … 14 15 16 17 18 … 21
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!